NCT01593670 arm group 15f90549f2c0f15ef9cf85ba405de03a [clinicaltrials_resource:NCT01593670/arm-group/15f90549f2c0f15ef9cf85ba405de03a]
Interleukin-2 [clinicaltrials_resource:03351d19a4e53c9cc7d6af196e4f49ee]Vorinostat [clinicaltrials_resource:1f3efeaabc0d13bbe7d27e67037bdcc5]Natural killer (NK) cells [clinicaltrials_resource:5d308bdf041a9366ccaa6733d976cc32]Decitabine [clinicaltrials_resource:68c65611dbd787e1b70adb073564620a]clinicaltrials:NCT01593670
arm group [clinicaltrials_vocabulary:arm-group]
NCT01593670 arm group 15f90549f2c0f15ef9cf85ba405de03a [clinicaltrials_resource:NCT01593670/arm-group/15f90549f2c0f15ef9cf85ba405de03a]
Bio2RDF identifier
NCT01593670/arm-group/15f90549f2c0f15ef9cf85ba405de03a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... f90549f2c0f15ef9cf85ba405de03a
description [clinicaltrials_vocabulary:description]
Patients who received treatmen ...... eeks after cycle 1 start date.
identifier
clinicaltrials_resource:NCT01593670/arm-group/15f90549f2c0f15ef9cf85ba405de03a
title
NCT01593670 arm group 15f90549f2c0f15ef9cf85ba405de03a
@en
type
label
NCT01593670 arm group 15f90549 ...... 90549f2c0f15ef9cf85ba405de03a]
@en